Mylan’s subsidiary Dey Pharma is set to offer EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine) Auto-Injector 0.3/0.15mg exclusively for the emergency treatment of severe allergic reactions (anaphylaxis). EpiPen and EpiPen Jr Auto-Injectors are intended for immediate self administration as emergency supportive therapy only.According to the guidelines given by the National Institute of Allergy and Infectious Diseases (NIAID), the patients who are at risk or who have experienced anaphylaxis have immediate access to two doses of epinephrine.
The guidelines indicate that if a patient responds poorly to the initial dose or has ongoing or progressive symptoms despite initial dosing, repeated dosing may be required after five to 15 minutes.Mylan president Heather Bresch said the decision to exclusively offer the EpiPen 2-Pak, which contains two single EpiPen Auto-Injectors, aligns with these guidelines, as well as with the 2011 World Allergy Organization (WAO) anaphylaxis guidelines which recommend that physicians consider prescribing more than one epinephrine auto-injector.
